N@N

Market Maker Surveillance Report. XOMA, SOL, DRRX, GUKYF, PCX, LIVE, Winning Stocks With Lowest Price Friction For Tuesday, Ju

July 3, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3509 companies with "abnormal" market making, 3926 companies with positive Friction Factors and 1468 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. XOMA LTD (NASDAQ:XOMA), RENESOLA LTD-ADR (NYSE:SOL), Durect Corp (NASDAQ:DRRX), GULF KEYSTONE PETROLEUM LTD (OTC:GUKYF), PATRIOT COAL CORP (NYSE:PCX), LIVEDEAL INC (NASDAQ:LIVE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  XOMA    $0.440    14.67%    564,596      52.40%    512,754      47.59%    51,842       1,178   
  SOL     $0.160    12.31%    402,171      39.58%    260,717      25.66%    141,454      8,841   
  DRRX    $0.110    11.82%    278,868      60.09%    185,216      39.91%    93,652       8,514   
  GUKYF   $0.570    20.50%    198,902      59.63%    67,378       20.20%    131,524      2,307   
  PCX     $0.480    34.78%    7,107,538    40.92%    6,227,340    35.85%    880,198      18,337  
  LIVE    $3.570    30.43%    110,586      54.50%    89,128       43.92%    21,458       60      

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows XOMA with a dollar gain Tuesday of $0.44000 and a Friction Factor of 1,178 shares. That means that it only took 1,178 more shares of buying than selling to move XOMA higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

XOMA LTD (NASDAQ:XOMA) - XOMA Ltd., incorporated in 1981, is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company has a royalty interest in one approved therapeutic antibody, RAPTIVA, which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis. XOMA also has a future royalty interest in additional therapeutic antibody product candidates being developed by others as a result of licensing its technologies. XOMA's pipeline includes both products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. In addition to supporting its product pipeline, the Company uses its infrastructure to provide process development and manufacturing services on a fee-for-service basis.

RAPTIVA (Efalizumab)

The Company markets RAPTIVA under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. RAPTIVA is a humanized therapeutic monoclonal antibody developed to treat immune system disorders. RAPTIVA can be self-administered by patients as a single, once-weekly subcutaneous injection. In 2005, Serono had launched RAPTIVA in over 40 countries worldwide.

RAPTIVA competes with Enbrel from Amgen Inc. and its partner Wyeth Pharmaceuticals; Amevive from Biogen Idec Inc.; BG-12 from Biogen Idec Inc. and Fumapharm AG; Remicade from Centocor, Inc. Humira from Abbott Laboratories, and ISA247 from Isotechnika, Inc.

CHIR-12.12

CHIR-12.12, which is being developed by the Company in collaboration with Chiron Corporation, is an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies. In April 2005, XOMA announced the initiation of Phase I study for patients with advance chronic lymphocytic leukemia (CLL). Then in October 2005, the Company initiated a second Phase I study for patients with multiple myeloma (MM).

NEUPREX (opebacan/rBPI21)

NEUPREX (opebacan/rBPI21) is an injectable formulation of rBPI21, a modified recombinant fragment of human bactericidal/permeability-increasing protein (BPI). BPI is a human host-defense protein made by a type of white blood cell that is involved in the body's defenses against microbial infection. In October of 2003, in conjunction with Children's Medical Center Dallas, the Company announced the initiation of an open-label, single center, dose escalation, investigator-sponsored, Phase I/II clinical trial of NEUPREX in pediatric patients with congenital heart abnormalities requiring open heart surgery associated with cardiopulmonary bypass.

XMA005.2

XMA005.2 is a Human Engineered monoclonal antibody with a high-affinity and potent inhibitory activity against its inflammatory target. This high potency means that it may be suitable for use as a monthly-dose injectable therapeutic. XOMA is evaluating XMA005.2 in preclinical studies targeting multiple indications, including osteoarthritis and rheumatoid arthritis, where less frequent dosing could be a significant marketing advantage.

Anti-gastrin Mab

In September of 2004, XOMA announced a worldwide collaboration with Aphton Corporation to develop treatments for gastrointestinal (GI) and other gastrin-sensitive cancers using anti-gastrin monoclonal antibodies. Gastrin has been shown to be involved in the progression of colorectal, stomach, liver and pancreatic cancers and inhibiting gastrin may inhibit such growth.

Metabolic Disease Target

The Company is co-developing Metabolic Disease Target with Lexicon Genetics. Metabolic Disease Target is a secreted protein involved in metabolic functions such as insulin sensitivity and weight gain that was identified through Lexicon's Knockout Technology. Antibodies to this target may be developed to treat Type II diabetes, obesity and other metabolic diseases.

MLN2222

MLN2222 (also known as CAB2) is being developed by XOMA in partnership with Millennium Pharmaceuticals, Inc. MLN2222 is a complement inhibitor for coronary artery bypass graft surgery tar

RENESOLA LTD-ADR (NYSE:SOL) - ReneSola Ltd, together with its subsidiaries, engages in the manufacture and sale of solar wafers and solar power products. It offers virgin polysilicons, monocrystalline and multicrystalline solar wafers, and photovoltaic cells and modules. The company also provides cell and module processing services. Its products are used in a range of residential, commercial, industrial, and other solar power generation systems. The company sells its solar wafers primarily to solar cell and module manufacturers. It principally operates in Mainland China, Singapore, Taiwan, Hong Kong, Korea, India, Australia, Germany, Italy, Spain, Belgium, France, the Czech Republic, and the United States. The company was founded in 2003 and is based in Jiashan, the Peoples Republic of China.

Durect Corp (NASDAQ:DRRX) - DURECT Corporation focuses on the development of pharmaceutical products for pain, central nervous system disorders, cardiovascular disease, and other chronic diseases based on its proprietary drug formulations and delivery platform technologies. Its products include Remoxy, an oxycodone gelatin capsule for chronic pain, which is accepted as a new drug application; POSIDUR, a release formulation of bupivacaine that is under Phase III clinical trial for post operative pain; ELADUR, a transdermal bupivacaine patch, which is under Phase II clinical trial, provides continuous delivery of bupivacaine for up to three days from a single application, as well as for the treatment of pain associated with post-herpetic neuralgia; and TRANSDUR-Sufentanil, a proprietary transdermal sufentanil patch, which is under Phase II clinical trial, provides continuous delivery of sufentanil for a period of up to seven days from a single application. The companys products also comprise oral controlled release opioid for pain that is under the Phase I clinical trial; and ORADUR-ADHD, a preclinical trial product targeting attention deficit hyperactivity disorder. It markets ALZET, the miniature implantable osmotic pumps and accessories for experimental research in mice, rats, and other laboratory animals. The company also develops and manufactures various biodegradable polymers based on lactide, glycolide, and caprolactone under the LACTEL brand for pharmaceutical and medical device clients, as well as conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies. The company has strategic agreements with Alpharma Ireland Limited; Nycomed Danmark, ApS; Pain Therapeutics, Inc.; Endo Pharmaceuticals Inc; Curaxis Pharmaceutical Corporation; ALZA Corporation; EpiCept Corporation; NeuroSystec Corporation; and King Pharmaceuticals, Inc. DURECT Corporation was founded in 1998 and is based in Cupertino, California.

GULF KEYSTONE PETROLEUM LTD (OTC:GUKYF) - Gulf Keystone Petroleum Limited, together with its subsidiaries, engages in the exploration, development, evaluation, and production of oil and gas properties in the Kurdistan Region of Northern Iraq and the Republic of Algeria. It also offers geological, geophysical, engineering, and administration services. The company was founded in 2001 and is based in Hamilton, Bermuda.

PATRIOT COAL CORP (NYSE:PCX) - Patriot Coal Corporation engages in the production and sale of thermal coal in the United States. It has operations and coal reserves in Appalachia and the Illinois basin. The company provides its thermal coal to electric utilities, as well as metallurgical coal to steel mills and independent coke producers. It has 14 company-operated mines, contractor-operated mines, and coal preparation facilities that are located in West Virginia and Kentucky. As of December 31, 2009, the company controlled approximately 1.8 billion tons of proven and probable coal reserves. Patriot Coal Corporation, through its subsidiary, Magnum Coal Company, operates 8 mining complexes with production from surface and underground mines located in Appalachia, as well as controls approximately 600 million tons of proven and probable coal reserves. The company is based in St. Louis, Missouri.

LIVEDEAL INC (NASDAQ:LIVE) - LiveDeal, Inc., together with its subsidiaries, delivers local customer acquisition services for small and medium-sized businesses. Its services are combined with an Internet Yellow Pages directory to deliver various ways for businesses via Internet through its online property, livedeal.com. The company, formerly known as YP Corp., was founded in 1968 and is headquartered in Las Vegas, Nevada.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net